The structural basis of T cell activation by superantigens

Annual Review of Immunology

Volumn 17, Issue , 1999, Pages 435-466

  Li, Hongmin ^a   Llera, Andrea ^a   Malchiodi, Emilio L ^a,b   Mariuzza, Roy A ^a  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Staphylococcal enterotoxins; T cell receptor; T cell stimulation; Three dimensional structure

Indexed keywords

SUPERANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN BINDING; ANTIGEN RECOGNITION; CLONAL ANERGY; FOOD POISONING; HUMAN; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; T LYMPHOCYTE ACTIVATION; TOXIC SHOCK SYNDROME;

AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNE DISEASES; FOOD POISONING; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; KINETICS; LYMPHOCYTE ACTIVATION; MACROMOLECULAR SUBSTANCES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SHOCK, SEPTIC; SUPERANTIGENS; T-LYMPHOCYTES;

EID: 0033008083     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.17.1.435     Document Type: Review

References (183)

1. Bentley GA, Mariuzza RA. 1995. The structure of the T cell antigen receptor. Annu. Rev. Immunol. 14:563-90
2. Wilson IA, Garcia KC. 1997. T-cell receptor structure and TCR complexes. Curr. Opin. Struct. Biol. 7:839-48
3. Kotzin BL, Leung DYM, Kappler J, Marrack P. 1993. Superantigens and their potential role in human disease. Adv. Immunol. 54:99-166
4. Scherer MT, Ignatowicz L, Winslow GM, Kappler JW, Marrack P. 1993. Superantigens: bacterial and viral proteins that manipulate the immune system. Annu. Rev. Cell. Biol. 9:101-128
5. Webb SR, Gascoigne NRJ. 1994. T-cell activation by superantigens. Curr. Opin. Immunol. 6:467-475
6. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. 1990. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit. Rev. Microbiol. 17:251-272
7. Betley MJ, Borst DW, Regassa LB. 1992. Staphylococcal enterotoxins, toxic shock syndrome toxin and streptococcal pyrogenic exotoxins: a comparative study of their molecular biology. Chem. Immunol. 55:1-35
8. Bohach GA. 1997. Staphylococcal enterotoxins B and C. In Superantigens: Molecular Biology, Immunology and Relevance to Human Disease, ed. DYM Leung, BT Huber, PM Schlievert, Marcel Dekker Inc. NY, pp. 167-198
9. Swaminathan S, Furey W, Pletcher J, Sax M. 1992. Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature 359:801-806
10. Prasad GS, Earhart CA, Murray DL, Novick RP, Schlievert PM, Ohlendorf DH. 1993. Structure of toxic shock syndrome toxin-1. Biochemistry 32:13761-13766.
11. Acharya KR, Passalacqua EF, Jones EY, Harlos K, Stuart DI, Brehm RD, Tranter HS. 1994. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature 367:94-97
12. Hoffmann ML, Jablonski LM, Crum KK, Hackett SP, Chi Y-I, Stauffacher CV, Stevens DL, Bohach GA. 1994. Predictions of T cell receptor and major histocompatibility complex binding sites on staphylococcal enterotoxin C3. Infect. Immun. 62:3396-3407
13. Papageorgiou A, Acharya KR, Shapiro R, Passalacqua EF, Brehm RD, Tranter HS. 1995. Crystal structure of the superantigen enterotoxin C2 from Stapylococcus aureus reveals a zinc-binding site. Structure 3:769-779
14. Schad EM, Zaitseva I, Zaitsev VN, Dohlsten M, Kalland T, Schlievert PM, Ohlendorf DH, Svensson LA. 1995. Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J. 14:3292-3301
15. 2+-mediated homodimerization. EMBO J. 15:6832-6840
16. Roussell A, Anderson BF, Baker HM, Frasev JD, Baker EN. 1997. Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc-binding suggest a novel mode of interaction with MHC class II molecules. Nature Struct. Biol. 4:635-643
17. Vath GM, Earhart CA, Rago JV, Kim MH, Bohach GA, Schlievert PM, Ohlendorf DH. 1997. The structure of the superantigen exfoliative toxin A suggests a novel regulation as a serine protease. Biochemistry 36:1559-1566
18. Cavarelli J, Prevost G, Bourguet W, Moulinier L, Chevrier B, Delagoutte B, Bilwes A, Mourey L, Rifau S, Piemont Y, Moras D. 1997. The structure of Staphylococcus aureus epidermolytic toxin A, an atypic serine protease, at 1.7 Å resolution. Structure 5:813-824
19. Cole BC, Griffiths MM. 1993. Triggering and exacerbation of autoimmune arthritis by the Mycoplasma arthritidis superantigen MAM. Arthritis Rheumat. 36:994-1002
20. Ito Y, Abe J, Yoshino K, Takeda T, Koshaka T. 1995. Sequence analysis of the gene for a novel superantigen produced by Yersinia pseudotuberculosis and expression of the recombinant protein. J. Immunol. 154:5896-5906
21. Miyoshi-Akiyama T, Abe A, Kato H, Kawahara K, Narimatsu H, Uchiyama T. 1995. DNA sequencing of the gene encoding a bacterial superantigen, Yersinia pseudotuberculosis-derived mitogen (YPM), and characterization of the gene product, cloned YPM. J. Immunol. 154:5228-5234
22. Acha-Orbea H, MacDonald HR. 1995. Superantigens of mouse mammary tumor virus. Annu. Rev. Immunol. 13:459-486
23. Astoul E, Lafage M, Lafon M. 1996. Rabies superantigen as a Vβ T-dependent adjuvant. J. Exp. Med. 183:1623-1631
24. Dobrescu D, Ursea B, Pope M, Asch AS, Posnett DM. 1995. Enhanced HIV-1 replication in Vβ12 T cells due to human cytomegalovirus in monocytes: evidence for a putative herpesvirus superantigen. Cell 82:753-763
25. Sutkowski N, Palkama T, Ciurli C, Sekal R-P, Thorley-Lawson DA, Huber B. 1996. An Epstein-Barr virus-associated superantigen. J. Exp. Med. 184:971-980
26. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. 1997. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 90:303-313
27. Bentley GA, Boulot C, Karjalainen K, Mariuzza RA. 1995. Crystal structure of the β chain of a T cell antigen receptor. Science 267:1984-1987
28. Fields BA, Ober B, Malchiodi EL, Lebedeva MI, Braden B, Ysern X, Kim J-K, Shao X, Ward ES, Mariuzza RA. 1995. Crystal structure of the Vα domain of a T cell antigen receptor. Science 270: 1821-1824
29. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, Teyton L, Wilson IA. 1996. An αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 274:209-219
30. Housset D, Mazza G, Gregoire C, Piras C, Malissen B, Fontecilla-Camps JC. 1997. The three-dimensional structure of a T-cell antigen receptor VαVβ heterodimer reveals a novel arrangement of the Vβ domain. EMBO J. 16:4205-4216
31. Wang J, Lim K, Smolyar A, Teng M, Liu J, Tse AGD, Liu J, Hussey RE, Chishti Y, Thomson CTT, Sweet RM, Nathenson SG, Chang H, Sacchettini JC, Reinherz EL. 1998. Atomic structure of an αβ T cell receptor (TCR) heterodimer in complex with an anti TCR Fab fragment derived from a mitogenic antibody. EMBO J. 17:10-26
32. Li H, Lebedeva MI, Llera AS, Fields BA, Brenner MA, Mariuzza RA. 1998. Structure of the Vδ domain of a human γδ T-cell antigen receptor. Nature 391:502-506
33. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134-141
34. Garcia KC, Degano M, Pease LR, Huang M, Peterson PA, Teyton L, Wilson IA, 1998. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 279: 1166-1172
35. Ding Y-H, Smith KJ, Garboczi DN, Utz U, Biddison WE, Wiley DC. 1998. Two human T cell receptors hind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity 8:403-411
36. Fields BA, Malchiodi EL, Li H-M, Ysern X, Stauffacher CV, Schlievert PM, Karjalainen K, Mariuzza RA. 1996. Crystal structure of the β chain of a T-cell receptor complexed with a superantigen. Nature 384:188-192
37. Li H, Llera A, Tsuchiya D, Leder L, Ysern X, Schlievert PM, Karjalainen K, Mariuzza RA. 1998. Three-dimensional structure of the complex between a T cell receptor β chain and the superantigen staphylococcal enterotoxin B. Immunity
38. MacDonald HR, Lees RK, Baschieri S, Herrmann T, Lussow AR. 1993. Peripheral T-cell reactivity to bacterial superantigens in vivo: the response/anergy paradox. Immunol. Rev. 133:105-117
39. Woodland DL, Wen R, Blackman MA. 1997. Why do superantigens care about peptides? Immunol. Today 18:18-22
40. Kappler JW, Roehm N, Marrack P. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273-280
41. MacDonald HR, Schneider R, Lees RK, Howe RC, Acha-Orbea H, Festenstein H, Zinkernagel RM, Hengartner H. 1988. T-cell receptor Vβ use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature 332:40-45
42. Pullen AM, Bill J, Kubo RT, Marrack P, Kappler JW. 1991. Analysis of the interaction site for the self superantigen Mls1a on T cell receptor Vβ J. Exp. Med. 173:1183-1192
43. White J, Herman A, Pullen AM, Kubo R, Kappler JW, Marrack P. 1989. The Vβ-specific superantigen staphylococcal enterotoxin B: stimulation of mature T cells and clonal deletion in neonatal mice. Cell 56:27-35
44. 4 T cells by staphylococcal enterotoxin B. J. Exp. Med. 172:1091-1100
45. O'Hehir RE, Lamb JR. 1990. Induction of specific clonal anergy in human T lymphocytes by Staphylococcus aureus enterotoxins. Proc. Natl. Acad. Sci. USA 87:8884-8888
46. + T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature 349:245-248
47. Golovkina TV, Chervonsky A, Dudley JP, Ross SR. 1992. Transgenic mouse mammary tumor virus superantigen expression prevents viral infection. Cell 69:637-645
48. Held W, Waanders G, Shakov AN, Scarpellino L, Acha-Orbea H, MacDonald HR. 1993. Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission. Cell 74:529-540
49. Ignatowicz L, Kappler J, Marrack P. 1992. The effects of chronic infection with a superantigen-producing virus. J. Exp. Med. 175:917-923
50. Golovkina TV, Dudley JP, Jaffe A, Ross SR. 1995. Mouse mammary tumor viruses with functional superantigen genes are selected during in vivo infection. Proc. Natl. Acad. Sci. USA 92:4828-4832
51. Wrona TJ, Lozano M, Binhazim AA, Dudley JP. 1998. Mutational and functional analysis of the C-terminal region of the C3H mouse mammary tumor virus superantigen. J. Virol. 72:4746-4755
52. Deresiewicz RL. 1997. Staphylococcal toxic shock syndrome. In Superantigens: Molecular Biology, Immunology and Relevance to Human Disease, ed. DYM Leung, BT Huber, PM Schlievert, Marcel Dekker Inc. NY, pp. 435-479
53. Stevens DL. 1997. Streptococcal toxic shock syndrome. In Superantigens: Molecular Biology, Immunology and Relevance to Human Disease, ed. DYM Leung, BT Huber, PM Schlievert, Marcel Dekker Inc. NY, pp. 481-501
54. Rago JV, Schlievert PM. 1998. Mechanisms of pathogenesis of staphylococcal and streptococcal superantigens. Curr. Top. Microbiol. Immunol. 225:81-97
55. Alber G, Hammer DK, Fleischer B. 1990. Relationship between enterotoxic- and T lymphocyte-stimulating activity of Staphylococcal enterotoxin. Br. J. Immunol. 144:4501-4506
56. Harris TO, Grossman D, Kappler JW, Marrack P, Rich RR, Betley MJ. 1993. Lack of complete correlation between emetic and T cell stimulatory activities of Staphylococcal enterotoxins. Infect. Immun. 61:3175-3183
57. Hovde CJ, Marr JC, Hoffmann ML, Hackett SP, Chi YI Crum KK, Stevens DL, Stauffacher CV, Bohach GA. 1994. Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1. Mol. Microbiol. 13:897-909
58. Sears CL, Kaper JB. 1996. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol. Rev. 60:167-215
59. Hamad ARA, Marrack P, Kappler JW. 1997. Transcytosis of staphylococcal superantigen toxins. J. Exp. Med. 185: 1447-1454
60. Rose NR, Wolfgram LJ, Herskowitz A, Beisel KW. 1986. Postinfectious autoimmunity: two distinct phases of coxsackie B3-induced myocarditis. Ann. N.Y. Acad. Sci. 475:146-156
61. Ray CG, Palmer JP, Crossley JR, Williams RH. 1980. Coxsackie B virus antibody responses in juvenile-onset diabetes mellitus. Clin. Endocrinol. 12:375-378
62. Oldstone MBA. 1990. Molecular mimicry and autoimmune disease. Cell 50: 819-820
63. Wucherpfenning KW, Strominger JL. 1995. Molecular mimicry in T-cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:695-705
64. Hemmer B, Fleckenstein BT, Vergelli M, Jung G, McFarland H, Martin R. 1997. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J. Exp. Med. 185:1651-1659
65. Renno T, Acha-Orbea H. 1996. Superantigens in autoimmune disease: still more shades of gray. Immunol. Rev. 154: 175-191
66. Bach JF. 1995. T cell receptor use in organ-specific human autoimmune diseases other than rheumatoid arthritis and multiple sclerosis. Ann. N.Y. Acad. Sci. 756:453-459
67. Traugott U. 1987. Multiple sclerosis: relevance of class I and class II MHC-expressing cells to lesion development. J. Neuroimmunol. 16:283-302
68. Olerup O, Hillert J. 1990. HLA class II associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 38:1-5
69. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. 1990. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247:718-721
70. Wucherpfennig KW, Zhang J, Witek C, Matsui M, Modabber Y, Ota K, Hafler DA. 1994. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J. Immunol. 150:5581-5592
71. Zhang J, Markovic S, Lacet B, Raus J, Weiner HL, Hafler DA. 1994. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179: 973-984
72. Stinissen P, Raus J, Zhang J. 1997. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit. Rev. Immunol. 17:33-75
73. Brocke S, Gaur A, Piercy C, Gautam K, Gijbels C, Fathman CG, Steinman L. 1993. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 365:642-644
74. Racke MK, Quigley L, Cannella B, Raine C, McFarlin DE, Scott DE. 1994. Superantigen modulation of experimental allergic encephalomyelitis: activation or anergy determines outcome. J. Immunol. 152:2051-2059
75. Brocke S, Hausmann S, Steinman L, Wucherpfennig KW. 1998. Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system. Sem. Immunol. 10:57-67
76. Paliard X, West SG, Lafferty JA, Clements JR, Kappler JW, Marrack P, Kotzin BL. 1991. Evidence for the effects of a superantigen in rheumatoid arthritis. Science 253:325-329
77. Haqqi TM, Anderson GD, Banerjee S, David CS. 1992. Restricted heterogeneity in T-cell antigen receptor Vβ gene usage in the lymph nodes and arthritic joints of mice. Proc. Natl. Acad. Sci. USA 89:1253-1255
78. Osman GE, Toda M, Kanagawa O, Hood LE. 1993. Characterization of the T cell receptor repertoire causing collagen arthritis in mice. J. Exp. Med. 177:387-395
79. Chiocchia G, Boissier MC, Fournier C. 1991. Therapy against murine collagen-induced arthritis with T-cell receptor Vβ-specific antibodies. Eur. J. Immunol. 21:2899-2905
80. Moder KG, Luthra HS, Griffiths M, David CS. 1993. Prevention of collagen-induced arthritis in mice by depletion of T cell receptor Vβ8 bearing T cells with monoclonal antibodies. Br. J. Rheumat. 32:26-30
81. + T cells in recovery from antigen-induced autoimmune disease. J. Exp. Med. 178:909-916
82. Kumar V, Stellrecht K, Sercarz E. 1996. Inactivation of CD4 regulatory T cells results in chronic autoimmunity. J. Exp. Med. 184:1609-1617
83. Kumar V, Aziz F, Sercarz E, Miller A. 1997. Regulatory T cells specific for the same framework 3 region of the Vβ8.2 chain are involved in the control of collagen II-induced arthritis and experimental autoimmune encephalomyelitis. J. Exp. Med. 185:1725-1733
84. Singh B, Prange S, Jevnikar AM. 1998. Protective and destructive effects of microbial infection in insulin-dependent diabetes mellitus. Sem. Immunol. 10:79-86
85. Conrad B, Weldmann E, Trucco G, Rudert WA, Behboo R, Ricordi C, Rodriquez-Rilo H, Finegold D, Trucco M. 1994. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371:351-355
86. Luppi P, Trucco M. 1996. Superantigens in insulin-dependent diabetes mellitus. Springer Semin. Immunopathol. 17:333-362
87. Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, Leung DY. 1992. Selective expansion of T cells expressing T-cell receptor variable region Vβ2 and Vβ8 in Kawasaki disease. Proc. Natl. Acad. Sci. USA 89:4066-4070
88. Abe J, Kotzin BL, Meissner C, Melish ME, Takahashi M, Fulton D, Romagne F, Malissen B, Leung DYM. 1993. Characterization of T cell receptor changes in acute Kawasaki disease. J. Exp. Med. 177:791-796
89. Curtis N, Zheng R, Lamb JR, Levin M. 1995. Evidence for a superantigen-mediated process in Kawasaki disease. Arch. Dis. Child. 72:308-311
90. Leung DY, Giorno RC, Kazemi LV, Flynn PA, Busse JB. 1995. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J. Immunol. 155:5018-5021
91. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. 1993. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 342:1385-1388
92. Pietra BA, De Inocencio J, Giannini EH, Hirsch R. 1994. TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J. Immunol. 153:1881-1888
93. + T helper cells. Clin. Exp. Immunol. 99:276-282
94. Jason J, Montana E, Donald JF, Seidman M, Inge KL, Campbell R. 1998. Kawasaki disease and the T-cell antigen receptor. Hum. Immunol. 59:29-38
95. Iandolo JJ, Chapes SK. 1997. The exfoliative toxins of Staphylococcus aureus. In Superantigens: Molecular Biology, Immunology and Relevance to Human Disease, ed. DYM Leung, BT Huber, PM Schlievert, Marcel Dekker Inc. NY, pp. 231-255
96. Prevost G, Rifai S, Chaix ML, Piemont Y. 1991. Functional evidence that the Ser-195 residue of staphylococcal exfoliative toxin A is essential for biological activity. Infect. Immun. 59:3337-3339
97. Henderson CA, Highet AS. 1988. Acute psoriasis associated with Lancefield group C and group G cutaneous streptococcal infections. Br. J. Dermatol. 118: 559-562
98. Lewis HM, Baker BS, Bokth S, Powles AV, Garioch JJ, Valdimarsson H, Fry L. 1993. Restricted T cell receptor Vβ gene usage in the skin of patients with guttate and chronic plaque psoriasis. Br. J. Dermatol. 129:514-520
99. + T cells in psoriatic lesions preferentially use T-cell receptor Vbeta 3 and/or Vbeta 13.1 genes. Proc. Natl. Acad. Sci USA 91:9282-9286
100. Leung DYM, Travers JB, Giorno R, Norris DA, Skinner R, Aelion J, Kazemi LV, Kim MH, Trumble AE, Kotb M, Schlievert PM. 1995. Evidence for streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest. 96:2106-2112
101. Bochncke WH, Dressel D, Manfras B, Zollner TM, Wettstein A, Bohm BO, Sterry W. 1995. T-cell repertoire in chronic plaque-stage psoriasis is restricted and lacks enrichment of superantigen associated Vβ regions. J. Invest. Dermatol. 104:725-728
102. Sayama K, Midorikawa K, Hanakawa Y, Sugai M, Hashimoto K. 1998. Superantigen production by Staphylococcus aureus in psoriasis. Dermatology 196:194-198
103. Leung DY. 1995. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J. Allergy Clin. Immunol. 96:302-318
104. Leyden JJ, Marples RR, Klingman AM. 1974. Staphylococcus aureus in the lesions of atopic dermatitis. Br. J. Dermatol. 90:525-530
105. Leung DY, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA, Hanifin JM, Sampson HA. 1993. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis: evidence for a new group of allergens. J. Clin. Invest. 92:1374-1380
106. Gascoigne NRJ, Ames KT. 1991. Direct binding of secreted T-cell receptor β chain to superantigen associated with class II major histocompatibility complex protein. Proc. Natl. Acad. Sci. USA 88:613-616
107. Malmqvist M. 1993. Surface plasmon resonance for detection and measurement of antigen-antibody affinity and kinetics. Curr. Biol. 5:282-286
108. Margulies DH, Plaskin D, Khilko SN, Jelonek MT. 1996. Studying interactions involving the T-cell antigen receptor by surface plasmon resonance. Curr. Opin. Immunol. 8:262-270
109. Seth A, Stern LS, Ottenhoff THM, Engel I, Owen MJ, Lamb JR, Klausner RD, Wiley DC. 1994. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature 369:324-327
110. Malchiodi EL, Eisenstein E, Fields BA, Ohlendorf DH, Schlievert PM, Karjalainen K, Mariuzza RA. 1995. Superantigen binding to a T cell receptor β chain of known three-dimensional structure. J. Exp. Med. 182:1833-1845
111. Leder L, Llera A, Lavoie PM, Lebedeva MI, Li H, Sekaly R-P, Bohach GA, Gahr PJ, Schlievert PM, Karjalainen K, Mariuzza RA. 1998. A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor β chain and major histocompatibility complex class II. J. Exp. Med. 187:823-833
112. Khandekar SS, Brauer PP, Naylor JW, Chang H-C, Kern P, Newcomb JR, LeClair KP, Stump HS, Bettencourt BM, Kawasaki E, Banerji J, Profy AT, Jones B. 1997. Affinity and kinetics of the interactions between an αβ T-cell receptor and its superantigen and class II-MHC/peptide ligands. Mol. Immunol. 34:493-503
113. van der Merwe PA, Brown MH, Davis SJ, Barclay AN. 1993. Affinity and kinetics of the interaction of the cell adhesion molecules rat CD2 and CD48. EMBO J. 12:4945-4954
114. van der Merwe PA, Barclay AN, Mason DW, Davis EA, Morgan BP, Tone M, Krishnam AKC, Ianelli C, Davis SJ. 1994. Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. Biochemistry 33:10149-10160
115. Corr M, Slanetz AE, Boyd LF, Jelonek MT, Khilko S, Al-Ramadi BK, Kim YS, Maher SE, Bothwell AL, Margulies DH. 1994. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science 265:946-948
116. k complexes: correlation of the dissociation rate with T-cell responsiveness. Proc. Natl. Acad. Sci. USA 91:12862-12866
117. Alam SM, Travers PJ, Wung JL, Nasholds W, Redpath S, Jameson SC, Gascoigne NRJ. 1996. T-cell receptor affinity and thymocyte positive selection. Nature 381:616-620
118. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. 1995. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 375:148-151
119. Viola A, Lanzavecchia A. 1996. T cell activation determined by T cell receptor number and tunable thresholds. Science 273:104-106
120. Rabinowitz JD, Beeson C, Lyons DS, Davis MM, McConnell HM. 1996. Kinetic discrimination in T-cell activation. Proc. Natl. Acad. Sci. USA 93:1401-1405
121. Proft T, Fraser J. 1998. Superantigens: just like peptides only different. J. Exp. Med. 187:819-821
122. Jardetzky TS, Brown JH, Gorga JC, Urban RG, Chi YI, Stauffacher C, Strominger JL, Wiley DC. 1994. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368:711-718
123. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. 1997. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7:473-481
124. Kim J, Urban RG, Strominger JL, Wiley DC. 1994. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 266:1870-1874
125. Mollick JA, Chintagumpala M, Cook RG, Rich RR. 1991. Staphylococcal exotoxin activation of T-cells. Role of exotoxin-MHC class II binding affinity and class II isotype. J. Immunol. 146:463-468
126. Wen R, Cole GA, Surman S, Blackman MA, Woodland DL. 1996. Major histocompatibility complex class II-associated peptides control the presentation of bacterial superantigens to T cells. J. Exp. Med. 183:1083-1092
127. Kozono H, Parker D, White J, Marrack P, Kappler J. 1995. Multiple binding sites for bacterial superantigens on soluble class II molecules. Immunity 3:187-196
128. Hudson KR, Tiedemann RE, Urban RG, Lowe SC, Strominger JL, Fraser JD. 1995. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. J. Exp. Med. 182:711-720
129. Abrahmsen L, Dohlsten M, Segren S, Bjork P, Jonsson E, Kalland T. 1995. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J. 14:2978-2986
130. Tiedemann RE, Urban RJ, Strominger JL, Fraser JD. 1995. Isolation of HLA-DR1.(staphylococcal enterotoxin A)2 trimers in solution. Proc. Natl. Acad. Sci. USA 92:12156-12159
131. Mehindate K, Thibodeau J, Dohlsten M, Kalland T, Sekaly R-P, Mourad W. 1995. Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A is a requirement for inflammatory cytokine gene expression. J. Exp. Med. 182:1573-1577
132. Tiedemann RE, Fraser JD. 1996. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen -presenting cell and T cell activation. J. Immunol. 157:3958-3966
133. Winslow GM, Marrack P, Kappler JW. 1994. Processing and major histocompatibility complex binding of the MTV7 superantigen. Immunity 1:23-33
134. Mottershead DG, Hsu P-N, Urban RG, Strominger JL, Huber BT. 1995. Direct binding of the Mtv7 superantigen (Mls-1) to soluble MHC class II molecules. Immunity 2:149-154
135. Held W, Waanders GA, MacDonald HR, Acha-Orbea H. 1994. MHC class II hierarchy of superantigen presentation predicts efficiency of infection with mouse mammary tumor virus. Int. Immunol. 6:1403-1407
136. Pucillo C, Cepeda R, Hodes RJ. 1993. Expression of a MHC class II transgene determines superantigenicity and susceptibility to mouse mammary tumor virus infection. J. Exp. Med. 178:1441-1445
137. Thibodeau J, Labrecque N, Denis F, Huber BT, Sekaly R-P. 1994. Binding sites for bacterial and endogenous retroviral superantigens can be dissociated on major histocompatibility complex class II molecules. J. Exp. Med. 179:1029-1034
138. Torres BA, Griggs ND, Johnson HM. 1993. Bacterial and retroviral superantigens share a common binding region on class II MHC antigens. Nature 364:152-154
139. McMahon CW, Bogatzki LY, Pullen AM. 1997. Mouse mammary tumor virus superantigens require N-linked glycosylation for effective presentation to T cells. Virology 228:161-170
140. Labrecque N, Thibodeau J, Mourad W, Sekaly R-P. 1994. T cell receptor-major histocombatibility complex class II interaction is required for the T cell response to bacterial superantigens. J. Exp. Med. 180:1921-1929
141. Deckhut AM, Chien Y, Blackman MA, Woodland DL. 1994. Evidence for a functional interaction between the β chain of major histocompatibility complex class II and the T cell receptor a chain during recognition of a bacterial superantigen. J. Exp. Med. 180:1931-1935
142. Blackman MA, Woodland DL. 1996. Role of the T cell receptor α-chain in supcrantigen recognition. Immunol. Res. 15:98-113
143. Padlan EA. 1994. Anatomy of the antibody molecule. Mol. Immunol. 31:169-217
144. b. Science 257:919-927
145. Madden D. 1995. The three-dimensional structure of peptide-MHC complexes. Annu. Rev. Immunol. 13:587-622
146. Bhat TN, Bentley GA, Boulot G, Greene MI, Tello D, Dall'Acqua W, Souchon H, Schwarz FP, Mariuzza RA, Poljak RJ. 1994. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc. Natl. Acad. Sci. USA 91:1089-1093
147. Fields BA, Goldbaum FA, Ysern X, Poljak RJ, Mariuzza RA. 1995. Molecular basis of antigen mimicry by an anti-idiotope. Nature 374:739-742
148. Dall'Acqua W, Goldman ER, Lin W, Teng C, Tsuchiya D, Li H, Ysern X, Braden BC, Li Y, Smith-Gill SJ, Mariuzza RA. 1998. A mutational analysis of binding interactions in an antigen-antibody protein-protein complex. Biochemistry 37:7981-7991
149. Hodtsev AS, Choi Y, Spanopoulou E, Posnett DN. 1998. Mycoplasma superantigen is a CDR3-dependent ligand for the T cell antigen receptor. J. Exp. Med. 187:319-327
150. Ciurli C, Posnett DN, Sekaly R-P, Denis F. 1998. Highly biased CDR3 usage in restricted sets of β chain variable regions during viral superantigen 9 response. J. Exp. Med. 187:253-258
151. Hong S-C, Waterbury G, Janeway CA Jr. 1996. Different superantigens interact with distinct sites in the Vβ domain of a single T cell receptor. J. Exp. Med. 183:1437-1446
152. Davies DR, Padlan EE. 1992. Twisting into shape. Curr. Biol. 2:254-256
153. Tulip WR, Varghese JN, Laver WG, Webster RG, Coleman PM. 1992. Refined crystal structure of the influenza virus N9 neuraminidase -NC41 Fab complex. J. Mol. Biol. 227:122-148
154. Wilson IA, Stanfield RL. 1993. Antigen-antibody interactions. Curr. Opin. Struct. Biol. 3:113-118
155. Lawrence MC, Coleman PM. 1993. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234:946-950
156. Ysern X, Li H, Mariuzza RA. 1998. Imperfect interfaces. Nature Struct. Biol. 5:412-414
157. Reich Z, Boniface JJ, Lyons DS, Borochov N, Wachtel EJ, Davis MM. 1997. Ligand-specific oligomerization of T-cell receptor molecules. Nature 387:617-620
158. Imanishi KH, Igarashi H, Uchiyama T. 1990. Activation of murine T cells by streptococcal pyrogenic exotoxin A. J. Immunol. 145:3170-3176
159. Woodland DL, Blackman MA. 1993. How do T cell receptors, MHC molecules and superantigens get together? Immunol. Today 14:208-212
160. Borrero H, Donson D, Cervera C, Rexer C, Macphail S. 1995. T cell receptor Vα4 is expressed by a subpopulation of Vβ6 T cells that respond to the bacterial superantigen staphylococcal enterotoxin B. J. Immunol. 154:4247-4260
161. Donson D, Borrero H, Rutman M, Pergolizzi R, Malhado N, Macphail S. 1997. Gene transfer directly demonstrates a role for TCR Vα elements in superantigen recognition. J. Immunol. 158:5229-5236
162. Daly K, Nguyen P, Hankley D, Zhang WJ, Woodland DL, Blackman MA. 1995. Contribution of the TCR α chain to the differential recognition of bacterial and retroviral superantigens. J. Immunol. 155:27-34
163. Abrahmsén L. 1995. Superantigen engineering. Curr. Opin. Struct. Biol. 5:464-470
164. Dohlsten M, Hedlund G, Åkerblom E, Lando PA, Kalland T. 1991. Monoclonal antibody-targeted superantigens: A different class of anti-tumor agents. Proc. Natl. Acad. Sci. USA 88:9287-9291
165. Dohlsten M, Abrahmsén L, Björk P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NRJ, Förberg C, Lind P, Kalland T. 1994. Monoclonal antibody-superantigen fusion proteins: Tumor-specific agents for T-cell-based tumor therapy. Proc. Natl. Acad. Sci. USA 91:8945-8949
166. Ihle J, Holzer U, Krull F, Dohlsten M, Kalland T, Niethammer D, Dannecker GE. 1995. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines. Cancer Res. 55:623-628
167. Holzer U, Bethge W, Krull F, Ihle J, Handgretinger R, Reisfeld RA, Dohlsten M, Kalland T, Niethammer D, Dannecker GE. 1995. Superantigen-staphylococcal enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells. Cancer Immunol. Immunother. 41:129-136
168. Hansson J, Ohlsson L, Persson R, Andersson G, Ilbäck N-G, Litton MJ, Kalland T, Dohlsten M. 1997. Genetically engineered superantigens as tolerable antitumor agents. Proc. Natl. Acad. Sci. USA 94:2489-2494
169. Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson PO, Kalland T, Dohlsten M, Persson B, Weiner LM. 1997. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J. Clin. Oncol. 15:1994-2007
170. Kappler JW, Herman A, Clements J, Marrack P. 1992. Mutations defining functional regions of the supcrantigen staphylococcal enterotoxin B. J. Exp. Med. 175:387-396
171. Bavari S, Dyas B, Ulrich RG. 1996. Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A. J. Infect. Dis. 174:338-345
172. Tseng J, Komisar JL, Trout RN, Hunt RE, Chen JY, Johnson AJ, Pitt L, Ruble DL. 1995. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid containing microspheres. Infect. Immun. 63:2880-2885
173. Lowell GH, Colleton C, Frost D, Kaminski RW, Hughes M, Hatch J, Hooper C, Estep J, Pitt L, Topper M, Hunt RE, Baker W, Baze WB. 1996. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect. Immun. 64:4686-4693
174. McCormack JE, Callahan JE, Kappler J, Marrack PC. 1993. Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J. Immunol. 150:3785-3792
175. Miethke T, Wahl C, Heeg K, Wagner H. 1993. Acquired resistance to superantigen-induced T cell shock. Vβ selective T cell unresponsiveness unfolds directly from a transient state of hyperreactivity. J. Immunol. 150:3776-3784
176. Kim C, Siminovitch KA, Ochi A. 1991. Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment. J. Exp. Med. 174:1431-1437
177. Rott O, Wekerle H, Fleischer B. 1992. Protection from experimental allergic encephalomyelitis by application of a bacterial superantigen. Int. Immunol. 4:347-353
178. Soos JM, Schiffenbauer J, Johnson HM. 1993. Treatment of PL/J mice with superantigen staphylococcal enterotoxin B, prevents development of experimental allergic encephalomyelitis. J. Neuroimmunol. 43:39-43
179. Racke MK, Quigley L, Cannella B, Raine C, McFarlin DE, Scott DE. 1994. Superantigen modulation of experimental allergic encephalomyelitis: activation or anergy determines outcome. J. Immunol. 152:2051-2059
180. Leung DYM, Schlievert PM. 1997. Superantigens in human disease. In Superantigens: Molecular Biology. Immunology and Relevance to Human Disease, ed. DYM Leung, BT Huber, PM Schlievert, Marcel Dekker Inc. NY, pp. 581-601
181. Hurley JM, Shimonkevitz R, Hanagan A, Enney K, Boen E, Malmstron S, Kotzin BL, Matsumura M. 1995. Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin-1. J. Exp. Med. 181:2229-2235
182. Murray DL, Prasad GS, Earhart CA, Leonard BAB, Kreiswirth BN, Novick RP, Ohlendorf DH, Schlievert PM. 1994. Immunobiologic and biochemical properties of mutants of toxic shock syndrome toxin-1. J. Immunol. 152:87-95
183. Deresiewicz RL, Wood J, Chan M, Finberg RW, Kasper DL. 1994. Mutations affecting the activity of toxic shock syndrome toxin-1. Biochemistry 33:12844-12851